AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.
Expert Rev Anticancer Ther
; 1(3): 341-7, 2001 Oct.
Article
en En
| MEDLINE
| ID: mdl-12113101
ABSTRACT
AE-941 (Neovastat) is a naturally occurring product extracted from cartilage and has antiangiogenic properties. It has reached Phase III clinical trial evaluation for the treatment of solid tumors (non-small cell lung cancer and renal cell carcinoma) and a pivotal Phase II clinical trial in multiple myeloma is ongoing. AE-941 inhibits several steps of the angiogenesis process, including matrix metalloproteinase activities and VEGF signaling pathways. Moreover, AE-941 induces endothelial cell apoptosis and tissue-type plasminogen activator activity, thus suggesting that it is a multifunctional antiangiogenic drug. Results from Phase I/II clinical trials indicate that AE-941, given orally, is well tolerated. Moreover, the median survival time in patients with renal cell carcinoma and non-small cell lung cancer was significantly longer in patients receiving high doses of AE-941 compared to low doses.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Extractos de Tejidos
/
Inhibidores de la Angiogénesis
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Expert Rev Anticancer Ther
Asunto de la revista:
NEOPLASIAS
/
TERAPEUTICA
Año:
2001
Tipo del documento:
Article
País de afiliación:
Canadá